Health Vidya

VIREAD™ is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. The following points should be considered when initiating therapy with VIREAD for the treatment of HIV-1 infection:The following points should be considered when initiating therapy with VIREAD for the treatment of HIV-1 infection: VIREAD should not be used in combination with ATRIPLA™, BIKTARVY™ COMPLERA™, DESCOVY™, GENVOYA™, ODEFSEY™, STRIBILD™, TRUVADA™ or VEMLIDY™ [See Warnings and Precautions (5.4)] . VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older . The following points should be considered when initiating therapy with VIREAD for the treatment of chronic hepatitis B infection: The indication in adults is based on safety and efficacy data from treatment of subjects who were nucleoside-treatment-naïve and subjects who were treatment-experienced with documented resistance to lamivudine. Subjects were adults with HBeAg-positive and HBeAg-negative chronic hepatitis B with compensated liver disease [See Clinical Studies (14.2)]. VIREAD was evaluated in a limited number of subjects with chronic hepatitis B and decompensated liver disease [See Adverse Reactions (6.1), Clinical Studies (14.2)] . The numbers of subjects in clinical trials who had adefovir resistance-associated substitutions at baseline were too small to reach conclusions of efficacy [See Microbiology (12.4), Clinical Studies (14.2)].